重度肥胖肝脏脂质组重塑表现为脂肪变性且不随非酒精性脂肪性肝炎演变
该研究纳入181例接受减重手术的患者,采用液相色谱-串联质谱分析肝脏、脂肪组织和血浆脂质组。结果显示肝脏脂质组随脂肪变性加重显著变化,但NASH相较于NAFL无进一步显著改变;血浆脂质与肝脏脂质强相关,加入血浆脂质变量可提高NASH诊断准确性(AUROC 0.667 vs. 0.785,p=0.025)。
要点
- 肝脏脂质组随脂肪变性加重而显著改变,但NASH相较NAFL无进一步显著变化
- 血浆脂质与肝脏脂质强相关,可作为NAFLD无创生物标志物的潜在来源
- 脂肪组织脂质组与NAFLD无相关性
核心结论
- 重度肥胖患者肝脏脂质组变化主要与脂肪变性相关,NASH阶段无额外显著改变。
研究设计与样本
- 研究纳入181例接受减重手术的患者,获取静脉血、肝脏、内脏和皮下脂肪组织样本。
- NAFLD严重程度通过组织学评估,脂质组分析采用液相色谱-串联质谱。
主要发现
- 肝脏脂质组随脂肪变性加重显著变化,三酰甘油、二酰甘油和鞘脂类(包括神经酰胺、二氢神经酰胺、己糖基神经酰胺和GM3神经节苷脂)增加。
- 这些脂质在血浆中随肝脂肪变性加重也增加,并与肝脏脂质强相关。
- 脂肪组织脂质组与NAFLD无相关性。
- NASH与NAFL相比,肝脏脂质无显著变化。
- 血浆脂质变量加入常规标志物后,NASH诊断准确性显著提高(AUROC 0.667 vs. 0.785,p=0.025)。
临床怎么用
- 血浆脂质组有潜力作为肥胖人群NAFLD的无创生物标志物,但需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUNDS & AIMS: Obesity often leads to non-alcoholic fatty liver disease (NAFLD), which can progress from simple steatosis (non-alcoholic fatty liver (NAFL)) to non-alcoholic steatohepatitis (NASH). The accumulation of certain lipid subtypes is linked with worsening metabolic and liver disease, however, specific changes during progression from No-NAFL to NAFL then NASH are unresolved. Herein, we characterise the liver, adipose tissue and plasma lipidome of worsening NAFLD in obesity, and evaluate the utility of plasma lipids as biomarkers of NAFLD. METHODS: Venous blood, liver, visceral and subcutaneous adipose tissue samples were obtained from 181 patients undergoing bariatric surgery. NAFLD severity was assessed histologically. Lipidomic analysis was performed using liquid chromatography-tandem mass spectrometry. RESULTS: The liver lipidome showed substantial changes with increasing steatosis, with increased triacylglycerols, diacylglycerols and sphingolipids including ceramide, dihydroceramide, hexosyl-ceramide and GM3 ganglioside species. These lipid species were also increased in plasma with increasing hepatic steatosis and showed strong correlations with liver lipids. Adipose tissue lipidomes showed no correlation with NAFLD. There were no significant changes in liver lipids with NASH compared to NAFL. The addition of plasma lipid variables to routine markers yielded significant improvements in diagnostic accuracy for NASH (AUROC 0.667 vs. 0.785, p = 0.025). CONCLUSION: Overall, these data provide a detailed description of the lipidomic changes with worsening NAFLD, showing significant changes with steatosis but no additional changes with NASH. Alterations in the liver lipidome are paralleled by similar changes in plasma. Further investigation is warranted into the potential utility of plasma lipids as non-invasive biomarkers of NAFLD in obesity. LAY SUMMARY: Non-alcoholic fatty liver disease (NAFLD) is characterised by distinct changes in the liver lipidome with steatosis. The development of non-alcoholic steatohepatitis (NASH) does not result in further changes in the lipidome. Lipids within body fat do not appear to influence the lipid profile of the liver or blood. Changes in liver lipids are paralleled by changes in blood lipids. This has potential to be developed into a non-invasive biomarker for NAFLD. CLINICAL TRIAL NUMBER: ACTRN12615000875505.
引用
- Ooi GJ, Meikle PJ, Huynh K, et al. Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis. J Hepatol. 2021. PMID: 33887358. doi:10.1016/j.jhep.2021.04.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。